Zhenyu Xu
About Zhenyu Xu
Zhenyu Xu is the Chief Scientific Officer at SOPHiA GENETICS, with a strong background in computational biology and bioinformatics. He holds a Ph.D. from the European Molecular Biology Laboratory and has extensive experience in analyzing clinical NGS data.
Current Role at SOPHiA GENETICS
Zhenyu Xu serves as the Chief Scientific Officer at SOPHiA GENETICS, a position he has held since 2021. In this role, he is responsible for overseeing the scientific direction and research initiatives of the company. His extensive background in bioinformatics and molecular biology supports the company's focus on advancing genomic data analysis and interpretation.
Previous Positions at SOPHiA GENETICS
Prior to his current role, Zhenyu Xu worked at SOPHiA GENETICS in various capacities. He was the Chief Technology Officer from 2014 to 2021, where he led technological advancements and innovations. Before that, he served as the Director of Bioinformatics from 2012 to 2014, contributing to the development of bioinformatics strategies and tools.
Education and Expertise
Zhenyu Xu holds a Bachelor's degree in Biology from Beijing Forestry University, which he completed from 2001 to 2004. He furthered his education at the University of Cambridge, obtaining a Master's degree in Computational Biology from 2005 to 2006. He earned his Ph.D. from the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast.
Research Experience at EMBL
Zhenyu Xu gained significant research experience at the European Molecular Biology Laboratory (EMBL). He completed his Ph.D. there from 2006 to 2010, followed by a post-doctoral fellowship from 2010 to 2012. His research involved systematically characterizing non-coding transcripts in yeast, contributing to the understanding of transcriptomic complexities.
Recognition in Bioinformatics
Zhenyu Xu is recognized as one of the most experienced bioinformaticians in clinical next-generation sequencing (NGS) data analysis worldwide. His expertise in this field enhances SOPHiA GENETICS' capabilities in genomic data interpretation, supporting the company's mission to improve patient outcomes through advanced genomic insights.